Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
In biotech, a single footnote can conceal years of lab work. Galapagos NV’s filings detail complex phase-2 oncology reads, milestone payments from AbbVie-era alliances, and the cost of its decentralized cell therapy platform. Investors track pipeline timelines and cash runway in minute detail, yet the raw documents are dense. Stock Titan turns that hassle into clarity—Galapagos NV SEC filings explained simply so you can focus on decisions, not deciphering.
Need the latest Galapagos NV quarterly earnings report 10-Q filing or curious how cash burn shifted after a new trial launch? Our AI-powered summaries spotlight R&D spend, patient enrollment metrics, and collaboration revenue in seconds. Real-time alerts push Galapagos NV Form 4 insider transactions real-time to your dashboard, while side-by-side charts offer Galapagos NV earnings report filing analysis without scrolling through exhibits. Compare segment spending quarter over quarter without opening a PDF.
From Galapagos NV insider trading Form 4 transactions and executive stock moves to an Galapagos NV 8-K material events explained after an FDA update, every document arrives the moment EDGAR posts it. You’ll also find the Galapagos NV annual report 10-K simplified, the Galapagos NV executive stock transactions Form 4 log, and a plain-English look at the Galapagos NV proxy statement executive compensation tables. Want help understanding Galapagos NV SEC documents with AI? It’s built in—complete coverage, instant context, smarter biotech investing.
Galapagos NV (GLPG) furnished a Form 6‑K as a foreign private issuer. The report attaches a press release dated October 23, 2025 as Exhibit 99.1 and incorporates it by reference into the company’s Registration Statements on Form S‑8.
The company indicates it files annual reports under cover of Form 20‑F. The Form 6‑K was signed by Company Secretary Annelies Denecker on October 24, 2025.
Galapagos NV furnished a Form 6-K and attached a press release dated October 16, 2025 as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, except for quotes by Henry Gosebruch and Fred Blakeslee, is incorporated by reference into its Registration Statements on Form S-8. Galapagos files annual reports on Form 20-F.
EcoR1 Capital files Amendment No. 3 to Schedule 13D on Galapagos NV (GLPG). The biotech-focused hedge fund and its founder Oleg Nodelman now report beneficial ownership of 8,714,522 ordinary shares/ADSs, equal to 13.22 % of the 65,897,071 shares outstanding (Form 20-F, 31 Dec 2024). The position is concentrated in EcoR1 Capital Fund Qualified, L.P. (8.19 m shares, 12.43 %) while EcoR1 Capital Fund, L.P. holds 0.52 m shares (0.79 %).
The shares were accumulated for an aggregate US$399.4 million; an additional US$293,693 in fees was paid to Citibank for converting ADSs into ordinary shares. EcoR1 and Mr Nodelman have shared voting and dispositive power over the entire stake.
Apart from updating share totals and cost, the filing makes no changes to the previously stated purpose of the investment or to any contracts, arrangements or relationships with the issuer. Exhibit 99.2 details trades executed in the past 60 days; no other transactions were disclosed.
FAQ
What is the current stock price of Galapagos Nv (GLPG)?
What is the market cap of Galapagos Nv (GLPG)?
